Diabetic Nephropathy Market - Global Report on Diabetic Nephropathy to 2020

  • Published on
    15-Jul-2015

  • View
    173

  • Download
    0

Embed Size (px)

Transcript

  • Diabetic Nephropathy Market - Global Study on Healthcare Cloud

    Computing : Asia to Witness Highest Growth by 2020

    Persistence Market Research

    Global Diabetic Nephropathy Market willreach $3,145.9 million in 2020: Persistence

    Market Research

    Persistence Market Research 1

  • Diabetic Nephropathy Market - Global Study on Healthcare Cloud

    Computing : Asia to Witness Highest Growth by 2020

    Persistence Market Research Released New Market Report Global Market Study on DiabeticNephropathy Market Asia to Witness Highest Growth by 2020,.The global diabeticnephropathy market was valued at USD 2,262.2 million in 2014 and is expected to grow at aCAGR of 5.6% from 2014 to 2020, to reach an expected value of USD 3,145.9 million in2020.

    Browse the full Global Market Study on Diabetic Nephropathy Market: Asia to WitnessHighest Growth by 2020 report at http://www.persistencemarketresearch.com/market-research/diabetic-nephropathy-market.asp

    Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significantcomplications in terms of mortality and morbidity for patients with diabetes. Globally, thediabetic nephropathy market is witnessing significant growth due to increasing prevalence ofdiabetes and obesity in different regions of the world. In addition, increasing R&Dinvestments in drug discovery and development and raising awareness about diabetes andkidney-related disorders are also driving the growth of the market. However, stringentregulatory requirements and longer approval time for drugs as well as the lack ofcomprehensive therapeutic management for diabetic nephropathy are inhibiting the growthof diabetic nephropathy market. The global diabetic nephropathy market is estimated atUSD 2,262.2 million in 2014. It is likely to grow at a CAGR of 5.6% from 2014 to 2020 toreach USD 3,145.9 million in 2020.

    In North America, various government programs are spreading awareness about diabetesand related renal complications. For instance, the National Kidney Disease EducationProgram, one of the major programs organized by the U.S. government, for increasingawareness about the various kidney diseases. In addition, the number of diabetic patientsare also increasing in the region; according to the SciELO Public Health, approximately 35million people were affected with diabetes mellitus in 2000 and this number is expected toreach 64 million by 2025 in North America.

    In Europe, rise in healthcare expenditure for diabetes treatment and increasing prevalenceof diabetes in the various part of Europe is boosting the growth of the European diabeticnephropathy market. According to IDF, approximately 55.4 million people had diabetes in2010 and the number is expected to reach 66.5 million by 2030 in Europe. According to theIDF, healthcare expenditure for diabetes treatment was approximately USD 105.5 billion in2010 and is expected to reach USD 124.6 billion by 2030 in Europe.

    Asia represents the fastest growing region in the diabetic nephropathy market due to therise in a diabetic population in various countries such as Japan and the Southeast Asiancountries. According to the International Diabetes Federation (IDF), developing countries,

    Persistence Market Research 2

  • Diabetic Nephropathy Market - Global Study on Healthcare Cloud

    Computing : Asia to Witness Highest Growth by 2020

    such as India and China, are expected to have the highest number of diabetes mellituspatients compared to developed countries, such as the U.S. and Germany.

    Sanofi is one of the leading players in the diabetic nephropathy market. Other major playersin diabetic nephropathy market include Eli Lilly and Company, Mitsubishi Tanabe PharmaCorporation, Novartis AG, Pfizer, Inc., Abbott Laboratories, AbbVie, Inc., Bayer AG, Merck &Co., Inc., Bayer AG and Reata Pharmaceuticals, Inc.

    The global diabetic nephropathy market is segmented as follows:

    Diabetic nephropathy market, by model of treatment

    Disease Modifying Therapies Angiotensin-Converting Enzyme Inhibitors Angiotensin Receptor Blockers Diuretics Calcium Channel Blockers Renin Inhibitors Connective Tissue Growth Factor Inhibitors Antioxidant Inflammation Modulator Monocyte Chemoattractant Proteins Inhibitor Endothelin-A Receptor Antagonist G Protein-Coupled Receptors

    Diabetic nephropathy market, by geography

    North America U.S. Canada

    Europe Germany France U.K.

    Asia Japan China India

    Rest of the World (RoW)

    Persistence Market Research 3

  • Diabetic Nephropathy Market - Global Study on Healthcare Cloud

    Computing : Asia to Witness Highest Growth by 2020

    Market History:

    Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications

    in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized

    by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 day is known as

    macroalbuminuria. Globally, the diabetic nephropathy market is witnessing significant growth due to rise

    in the incidence of diabetes and obesity in different regions of the world. In addition, increasing R&D

    investments in drug discovery and development by various companies, such as Sanofi, Eli Lilly and

    Mitsubishi Tanabe Pharma is also driving the growth of the market. However, stringent regulatory

    requirements and longer approval time for drugs as well as the lack of comprehensive therapeutic

    management for diabetic nephropathy are inhibiting the growth of diabetic nephropathy market. The

    global diabetic nephropathy market is estimated at USD 2,262.2 million in 2014. It is likely to grow at a

    CAGR of 5.6% from 2014 to 2020 to reach USD 3,145.9 million in 2020.

    North America has the largest market for the global diabetic nephropathy market. However, In terms of

    growth, Asia is the fastest growing region. Disease Modifying Therapies (DMT) is the largest and fastest

    growing mode of treatment, whereas ACE inhibitors, is the largest and fastest growing DMT of diabetic

    nephropathy.

    North American market is estimated at USD 931.0 million in 2014 and is expected to reach USD 1,302.0

    million in 2020, growing at a CAGR of 5.7% from 2014 to 2020.

    The global DMT market is estimated at USD 2,093.5 million in 2014 and is expected to reach USD

    2,929.8 million in 2020, growing at a CAGR of 5.8% from 2014 to 2020.

    Persistence Market Research 4

  • Diabetic Nephropathy Market - Global Study on Healthcare Cloud

    Computing : Asia to Witness Highest Growth by 2020

    Table of Content

    Chapter 1 Preface

    1.1 Report Description

    1.2 Research Methodology

    1.3 Assumptions

    Chapter 2 Market Synopsis

    Chapter 3 Porters Five Forces Analysis

    3.1 Bargaining Power of Suppliers

    3.2 Bargaining Power of Buyers

    3.3 Threat of New Entrants

    3.4 Threat of Substitutes

    3.5 Intensity of Rivalry

    Persistence Market Research 5

  • Diabetic Nephropathy Market - Global Study on Healthcare Cloud

    Computing : Asia to Witness Highest Growth by 2020

    Chapter 4 Industry Overview

    4.1 Market Definition

    4.2 Market Drivers

    4.2.1 Increasing prevalence of diabetes

    4.2.2 Globally rising obesity increasing the prevalence of diabetes

    4.2.3 Increasing R&D investments in drug discovery and development

    4.2.4 Rising awareness among people about diabetes and kidney-related disorders

    4.3 Impact Analysis of Market Drivers

    4.4 Market Restraints

    4.4.1 Strict regulatory requirements and long approval time for drugs

    4.4.2 Lack of comprehensive therapeutic management for diabetic nephropathy

    4.5 Impact Analysis of Market Restraints

    4.6 Market Trends

    4.6.1 Increasing usage of combination therapy is gaining popularity in diabetic nephropathy

    market

    Chapter 5 Global Market Size and Forecast

    Chapter 6 Market Size and Forecast by Mode of Treatment

    6.1 Disease Modifying Therapies

    6.1.1 Angiotensin-Converting Enzyme Inhibitors

    6.1.2 Angiotensin Receptor Blockers

    6.1.3 Diuretics

    6.1.4 Calcium Channel Blockers

    6.1.5 Renin Inhibitors

    6.1.6 Connective Tissue Growth Factor Inhibitors

    6.1.7 Antioxidant Inflammation Modulator

    6.1.8 Monocyte Chemoattractant Proteins Inhibitor

    6.1.9 Endothelin-A Receptor Antagonist

    6.1.10 G Protein-Coupled Receptors

    Persistence Market Research 6

  • Diabetic Nephropathy Market - Global Study on Healthcare Cloud

    Computing : Asia to Witness Highest Growth by 2020

    Chapter 7 Market Size and Forecast by Geography

    7.1 North America

    7.1.1 Scenario in the U.S.

    7.1.2 Scenario in Canada

    7.2 Europe

    7.2.1 Scenario in Germany

    7.2.2 Scenario in France

    7.2.3 Scenario in the U.K.

    7.3 Asia

    7.3.1 Scenario in Japan

    7.3.2 Scenario in China

    7.3.3 Scenario in India

    Chapter 8 Pipeline Drugs for Diabetic Nephropathy

    8.1 Drugs Under Development for Diabetic Nephropathy

    Chapter 9 Competitive Scenario

    9.1 Competitive Benchmarking

    Chapter 10 Company Profiles

    10.1 Novartis AG

    10.1.1 Company overview

    10.1.2 Products and services

    10.1.3 Financial performance

    10.1.4 Key developments

    10.2 Merck & Co., Inc.

    10